Aldeyra Reports PDUFA Extension for Dry Eye Drug Reproxalap

PDUFA Date Extended for Aldeyra’s Reproxalap Dry Eye NDA Aldeyra Therapeutics a biotechnology company focused on the discovery and development of innovative therapies for immune-mediated and inflammatory diseases, has announced that the U.S. Food and Drug Administration (FDA) has extended…










